

Special Issue

Pancreatic Ductal Adenocarcinoma: From Pathophysiology to Novel Therapeutic Approaches 2.0

Message from the Guest Editors

Pancreatic cancer (PC) is one of the leading causes of cancer-related death worldwide, because of the propensity of the tumors to disseminate at an early stage, sustained by their complex microenvironment. At the time of diagnosis, only 20% of PC patients are eligible for surgical resection. Hence, there is an urgent need to find new therapeutic strategies that can be more specific and effective for treating PC patients. This Special Issue will provide insights regarding PC cells' molecular drivers, highlighting the impact of the tumor microenvironment on PC cells, and will discuss the implications for developing specific PC therapies. Authors are invited to submit their original research, communications, and review articles to this Special Issue of *Biomedicines*. Potential topics include, but are not limited to, the following: -The role of cancer stem cells or tumor-initiating cells in the genesis and progression of PC -The impact of the epigenetic changes in PC disease -Pancreatic tumor microenvironment -Role of the exosomes in PC - Prognostic and predictive biomarkers in PC -Novel targeted therapies in PC

Guest Editors

Prof. Dr. Rossano Lattanzio

Department of Innovative Technologies in Medicine and Dentistry, Center for Advanced Studies and Technology (CAST), University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy

Dr. Konstantinos Dimas

Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 341500 Larissa, Greece

Deadline for manuscript submissions

closed (31 October 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/75606

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).